1H-NMR-based urine metabolomics of prostate cancer and benign prostatic hyperplasia

Mohammed Zniber, Tarja Lamminen, Pekka Taimen, Peter J. Boström, Tan-Phat Huynh*

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

2 Citations (Scopus)
3 Downloads (Pure)

Abstract

Background: Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are prevalent conditions affecting a significant portion of the male population, particularly with advancing age. Traditional diagnostic methods, such as digital rectal examination (DRE) and prostate-specific antigen (PSA) tests, have limitations in specificity and sensitivity, leading to potential overdiagnosis and unnecessary biopsies. Significance: This study explores the effectiveness of 1H NMR urine metabolomics in distinguishing PCa from BPH and in differentiating various PCa grades, presenting a non-invasive diagnostic alternative with the potential to enhance early detection and patient-specific treatment strategies. Results: The study demonstrated the capability of 1H NMR urine metabolomics in detecting distinct metabolic profiles between PCa and BPH, as well as among different Gleason grade groups. Notably, this method surpassed the PSA test in distinguishing PCa from BPH. Untargeted metabolomics analysis also revealed several metabolites with varying relative concentrations between PCa and BPH cases, suggesting potential biomarkers for these conditions.

Original languageEnglish
Article numbere28949
JournalHeliyon
Volume10
Issue number7
DOIs
Publication statusPublished - 15 Apr 2024
MoE publication typeA1 Journal article-refereed

Keywords

  • Chemometrics
  • Metabolomics
  • NMR
  • Prostate cancer
  • Urine

Fingerprint

Dive into the research topics of '1H-NMR-based urine metabolomics of prostate cancer and benign prostatic hyperplasia'. Together they form a unique fingerprint.

Cite this